Commerce Bank Purchases Shares of 25,623 Sarepta Therapeutics, Inc. $SRPT

Posted by Brian Himes on Aug 28th, 2026

Commerce Bank purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the second quarter, HoldingsChannel.com reports. The fund purchased 25,623 shares of the biotechnology company’s stock, valued at approximately $460,000.

A number of other institutional investors and hedge funds have also modified their holdings of SRPT. Kestra Advisory Services LLC bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $25,000. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $25,000. Meeder Asset Management Inc. bought a new position in Sarepta Therapeutics in the 2nd quarter worth $27,000. Ancora Advisors LLC raised its holdings in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Finally, Allworth Financial LP lifted its position in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of recent analyst reports. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.06.

Check Out Our Latest Report on Sarepta Therapeutics

Sarepta Therapeutics Trading Up 10.9%

Shares of SRPT stock opened at $21.59 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The firm’s fifty day simple moving average is $17.66 and its 200 day simple moving average is $18.30. The firm has a market capitalization of $2.28 billion, a P/E ratio of -7.44, a price-to-earnings-growth ratio of 0.29 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same period in the prior year, the company earned $2.02 EPS. The business’s quarterly revenue was down 34.3% compared to the same quarter last year. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Sarepta Therapeutics Company Profile

(Free Report)

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.